ESM1 and diabetic kidney disease: Ekiz-Bilir et al. performed a study with type 2 DM patients (n = 96) with and without diabetic nephropathy to assess the predictive role of endocan and endoglin as markers of angiogenesis and diabetic nephropathy progression [53].